323 related articles for article (PubMed ID: 18584106)
1. [The role of the Committee for Medicinal Products for Human Use (CHMP) in the European centralised procedure].
Enzmann H; Schneider C
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):731-9. PubMed ID: 18584106
[TBL] [Abstract][Full Text] [Related]
2. [Marketing of medicinal products in the European Community. The Mutual Recognition and Decentralised Procedures].
Bachmann P
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):722-30. PubMed ID: 18560780
[TBL] [Abstract][Full Text] [Related]
3. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
Lehmann B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
[TBL] [Abstract][Full Text] [Related]
4. [EU law on marketing authorization of medicines. History, current state of development and perspectives].
Nettesheim M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):705-12. PubMed ID: 18560781
[TBL] [Abstract][Full Text] [Related]
5. Where is industry getting it wrong? A review of quality concerns raised at Day 120 by the Committee For Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for Chemical Entity Medicinal Products.
Borg JJ; Robert JL; Wade G; Aislaitner G; Pirozynski M; Abadie E; Salmonson T; Vella Bonanno P
J Pharm Pharm Sci; 2009; 12(2):181-98. PubMed ID: 19732496
[TBL] [Abstract][Full Text] [Related]
6. [Marketing authorization for pharmaceuticals: the necessity of European collaboration].
Seitz R; Enzmann H
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):703-4. PubMed ID: 18592336
[No Abstract] [Full Text] [Related]
7. [The regulatory framework for complementary and alternative medicines in Europe].
Knöss W; Stolte F; Reh K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
[TBL] [Abstract][Full Text] [Related]
8. [Harmonisation of the Marketing Authorisation Application dossier: perspectives due to harmonised requirements. Assessing Rules and the Common Technical Document].
Menges K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):748-56. PubMed ID: 18584104
[TBL] [Abstract][Full Text] [Related]
9. [European Agency for the Evaluation of Medicinal Products: five years experience].
Sauer F
Bull Mem Acad R Med Belg; 2000; 155(5-6):254-8; discussion 259-62. PubMed ID: 11304960
[TBL] [Abstract][Full Text] [Related]
10. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
Tomić S; Sucić AF; Martinac AI
Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
[TBL] [Abstract][Full Text] [Related]
11. [Revision of the Renewals Procedure and the implementation of the sunset clause. BfArM's experience with the amended legislation].
Horn M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):740-7. PubMed ID: 18584105
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency.
Regnstrom J; Koenig F; Aronsson B; Reimer T; Svendsen K; Tsigkos S; Flamion B; Eichler HG; Vamvakas S
Eur J Clin Pharmacol; 2010 Jan; 66(1):39-48. PubMed ID: 19936724
[TBL] [Abstract][Full Text] [Related]
13. [Registration of new medicinal products in Europe].
Singer E
Onkologie; 2008; 31 Suppl 2():64-6. PubMed ID: 18487872
[TBL] [Abstract][Full Text] [Related]
14. How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations.
Jahn EM; Schneider CK
N Biotechnol; 2009 Jun; 25(5):280-6. PubMed ID: 19491045
[TBL] [Abstract][Full Text] [Related]
15. [Master files: less paper, more substance. Special rules for special medicines: Plasma Master File and Vaccine Antigen Master File].
Seitz R; Haase M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):764-70. PubMed ID: 18560779
[TBL] [Abstract][Full Text] [Related]
16. [Europe and medicines: role of the EMEA].
Sauer F
Ann Pharm Fr; 2000 Jul; 58(4):278-85. PubMed ID: 10915977
[TBL] [Abstract][Full Text] [Related]
17. [How does a new medicine reach the patient?].
Visser BJ; Korevaar DA; Mokhles MM; Vermeer-Pragt W; de Boer A; Giezen TJ
Ned Tijdschr Geneeskd; 2020 Jul; 164():. PubMed ID: 32779914
[TBL] [Abstract][Full Text] [Related]
18. [Scientific advice by the nationally competent authority and by the EMEA on the conduct of clinical trials].
Dejas-Eckertz P; Schäffner G
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):423-8. PubMed ID: 15830253
[TBL] [Abstract][Full Text] [Related]
19. [The network of official medicines control laboratories].
Buchheit KH; Wanko R
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1139-44. PubMed ID: 25192832
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and its impact on benefit/risk considerations in the authorisation of biopharmaceuticals.
Büttel I; Völler K; Schneider C;
Curr Drug Saf; 2010 Oct; 5(4):287-92. PubMed ID: 20615175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
